Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Payers

How extended periods of suppressed utilization and a regulatory pause on record collection may influence plans' anticipated results next year.

Principal, Health and Life Sciences, Organizational Effectiveness, Oliver Wyman
Senior Advisor, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

How New Price Transparency Rules May Impact Payers and Providers

Immediate considerations for the industry.

Principal, Health and Life Sciences, Oliver Wyman
Global Head, Health Services, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Practice Leader, Oliver Wyman Actuarial Consulting

Despite HHS movement mandating that hospitals estimate patients' bills early on, the thing is, healthcare's already pretty shoppable.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

An analysis of annual premiums by federal poverty level.

Practice Leader, Oliver Wyman Actuarial Consulting

Fourteen percent of physicians offer virtual visits. But a new CMS rule may make telehealth more commonplace.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health and Life Sciences, Oliver Wyman
Senior Knowledge Expert, Health & Life Sciences, Oliver Wyman

Analysis on the potential effects of cost-sharing reduction payments and pass-through savings.

Partner, Oliver Wyman Actuarial Consulting
Practice Leader, Oliver Wyman Actuarial Consulting

In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Engagement Manager, Health & Life Sciences, Oliver Wyman

The impact of one proposal the US Senate is considering to fund CSR payments.

Partner, Oliver Wyman Actuarial Consulting
Practice Leader, Oliver Wyman Actuarial Consulting

Perceptions of behavioral health are evolving. Here’s why a multi-faceted approach to behavioral health brings more value to patients.

Principal, Health and Life Sciences, Oliver Wyman
Chief Medical Officer, AbleTo

Insights in your inbox

Subscribe